AbbVie and Pfizer chart distinct paths in revenue growth, risk, and valuation. Explore how their financials and strategies ...

Pfizer (NYSE: PFE) and Merck (NYSE: MRK) are two pharmaceutical giants that have lagged broader equities this year. Both have delivered unimpressive financial results recently, and are facing a ...

Pfizer PFE has committed significant resources toward the development of treatments in the fields of oncology, metabolic ...

Pfizer’s biggest competitors in the global pharmaceutical industry are Johnson & Johnson, Roche, Eli Lilly, AbbVie, Novo ...

As noted, Merck and Pfizer are both large pharmaceutical companies. Making and selling drugs is complex, expensive, and competitive. There are massive research and development costs involved in ...

The registrar ultimately concluded that the competing trademarks were “overall, dissimilar”. Read more at straitstimes.com.

A cancer-drug combination from Merck, Pfizer and Astellas Pharma has hit a key goal in a late-stage study in patients with a hard-to-treat form of bladder cancer. The companies on Tuesday said Merck's ...

Pfizer (NYSE:PFE) is accelerating its transformation with acquisitions of Seagen and Metsera to expand in oncology and anti obesity treatments. The company is dealing with lower COVID related revenues ...

Pfizer has at least two key candidates in the pipeline that look like future winners. Merck has launched several products in preparation for a massive upcoming patent cliff. One of these drugmakers ...

Pfizer and Merck are two of the largest drug companies on the planet. Both companies are dealing with upcoming patent expirations. Pfizer is making aggressive moves to solve the problem, which is ...